The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones

被引:280
作者
Arner, P [1 ]
机构
[1] Huddinge Univ Hosp, Dept Med, S-14186 Huddinge, Sweden
关键词
D O I
10.1016/S1043-2760(03)00024-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Globally, the prevalence of obesity is escalating, and insulin resistance resulting from increased (predominantly visceral) adipose tissue mass has been identified as a key factor that could drive parallel rises in type 2 diabetes mellitus (T2DM) prevalence. Correlations between these global epidemics have encouraged investigation into potential molecular links between the related impairments in lipid and glucose homeostasis. This article reviews factors released from adipose tissue that could contribute to the development of insulin resistance and beta-cell dysfunction, including tumour necrosis factor alpha RNF-alpha free fatty acids (FFAs), adiponectin, resistin and leptin. It also considers whether agonists of the peroxisome proliferator-activated receptor gamma, which is abundant in adipose tissue, might have an important impact on factors associated with adipocyte metabolism. For example, the thiazolidinediones, a class of oral anti-diabetic agents that reduce insulin resistance and improve beta-cell function, might mediate these effects by regulating adipocyte-derived factors, in particular TNF-alpha and FFAs.
引用
收藏
页码:137 / 145
页数:9
相关论文
共 65 条
  • [1] Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation
    Adams, M
    Montague, CT
    Prins, JB
    Holder, JC
    Smith, SA
    Sanders, L
    Digby, JE
    Sewter, CP
    Lazar, MA
    Chatterjee, VKK
    O'Rahilly, S
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) : 3149 - 3153
  • [2] Not all fat is alike
    Arner, P
    [J]. LANCET, 1998, 351 (9112) : 1301 - 1302
  • [3] Insulin resistance in type 2 diabetes: role of fatty acids
    Arner, P
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2002, 18 : S5 - S9
  • [4] Arner P, 2001, DIABETES OBES METAB, V3, pS11, DOI 10.1046/j.1463-1326.2001.00031.x
  • [5] Regional adipocity in man
    Arner, P
    [J]. JOURNAL OF ENDOCRINOLOGY, 1997, 155 (02) : 191 - 192
  • [6] BAK JF, 1992, DIABETOLOGIA, V35, P777
  • [7] Banerji M, 2001, DIABETES, V50, pA90
  • [8] NORMALIZATION OF THE INSULIN SENSITIVITY AND THE CELLULAR INSULIN BINDING DURING TREATMENT OF OBESE DIABETICS FOR ONE YEAR
    BECKNIELSEN, H
    PEDERSEN, O
    LINDSKOV, HO
    [J]. ACTA ENDOCRINOLOGICA, 1979, 90 (01): : 103 - 112
  • [9] Central role of the adipocyte in the metabolic syndrome
    Bergman, RN
    Van Citters, GW
    Mittelman, SD
    Dea, MK
    Hamilton-Wessler, M
    Kim, SP
    Ellmerer, M
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2001, 49 (01) : 119 - 126
  • [10] Absence of functional insulin receptor substrate-3 (IRS-3) gene in humans
    Björnholm, M
    He, AR
    Attersand, A
    Lake, S
    Liu, SCH
    Lienhard, GE
    Taylor, S
    Arner, P
    Zierath, JR
    [J]. DIABETOLOGIA, 2002, 45 (12) : 1697 - 1702